探讨mri的应用“维持”疾病亚型在复发和二次精密医学进步的女士(p15 - 4.002)

摘要目的:探索是否子类型化与机器学习算法的亚型和分期推理(维持)可以用来预测对富马酸二甲酯(DMF)和natalizumab (NTZ)。

背景:应用维持横断面大脑核磁共振数据,3多发性硬化症(MS)亚型(损伤、正常白质,cortex-led)可以被识别,并可能有不同的利率残疾的进展,复发率和治疗反应。

设计/方法:维持亚型数据可以从提升(阶段3的研究NTZ (n = 1002) secondary-progressive女士(spm))和定义/确认(第三阶段研究DMF (n = 365)的复发缓和女士[名RRMS])。定义/确认,比较局限于DMF 240毫克和安慰剂的手臂。基线维持亚型之间的关联概率和MS疾病特点和斯皮尔曼相关测试。治疗效果在96年新的T2病灶数周亚型被负二项回归估计,调整基线年龄、性别、持续时间、女士和基线Gd +计数和T2病灶体积。确定治疗效果不同亚型之间交互方面治疗和亚型之间补充道。

结果:所有研究lesion-led亚型与糟糕的大脑核磁共振疾病严重度基线测量T2病灶体积,规范化的脑容量,Gd +病灶计数(p < 0.05)。新的T2病灶计数和安慰剂在所有亚型降低了NTZ提升spm患者(p < 0.001)和DMF的定义/确认名RRMS患者(p < 0.05)。亚型之间无显著差异,观察治疗效果在spm NTZ或DMF名RRMS (p > 0.05)。

结论:维持lesion-led亚型与更高的基线脑MRI疾病严重程度相关。NTZ和DMF减少炎性疾病活动维持亚型与治疗反应无显著差异。维持子类型化女士没有歧视回答者异质性作为评估新的病变形成这些NTZ和DMF试验。

披露:Gafson博士没有披露。江博士已经收到生原体的个人作为一个雇员补偿。江博士获得了股票或生原体的所有者权益。沈博士已经收到生原体的个人作为一个雇员补偿。大为刘已经收到生原体的个人作为一个雇员补偿。大为刘已经收到了股票或生原体的所有者权益。佩雷亚先生曾获得股票或生原体的所有者权益。佩雷亚先生已经收到个人薪酬在100000 - 499999美元的范围作为老数据科学家生原体。阿诺德博士已经收到个人薪酬在500 - 4999美元的范围为Alexion担任顾问。阿诺德博士已经收到个人薪酬在10000 - 49999美元的范围作为顾问生原体。 Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Celgene. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Frequency Therapeutics. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Celgene. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shionogi. Dr. Arnold has received stock or an ownership interest from NeuroRx. The institution of Dr. Arnold has received research support from Novartis. The institution of Dr. Arnold has received research support from Immunotec. Colm Elliott has received personal compensation for serving as an employee of NeuroRx Research. Bing Zhu has received personal compensation for serving as an employee of Biogen. Bing Zhu has received stock or an ownership interest from Biogen. Elizabeth Fisher has received personal compensation for serving as an employee of Biogen. Elizabeth Fisher has received stock or an ownership interest from Biogen. Elizabeth Fisher has received intellectual property interests from a discovery or technology relating to health care. Prof. Ciccarelli has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Prof. Ciccarelli has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for NEUROLOGY Journal. Declan Chard has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Declan Chard has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hoffmann-La Roche. Declan Chard has received research support from MS Society. Declan Chard has received research support from Hoffmann-La Roche. Declan Chard has received research support from International Progressive MS Alliance. Declan Chard has received personal compensation in the range of $500-$4,999 for serving as a speaker with Novartis. Declan Chard has a non-compensated relationship as a trustee with MS Trust that is relevant to AAN interests or activities. Declan Chard has a non-compensated relationship as a editorial board member with Neurology that is relevant to AAN interests or activities. Declan Chard has a non-compensated relationship as a co-supervisor of a clinical fellowship at the National Hospital for Neurology and Neurosurgery, London, with Merck that is relevant to AAN interests or activities. Frederik Barkhof has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Frederik Barkhof has received personal compensation in the range of $0-$499 for serving as a Consultant for Biogen. Frederik Barkhof has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Combinostics. Frederik Barkhof has received personal compensation in the range of $500-$4,999 for serving as a Consultant for IXICO. Frederik Barkhof has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Frederik Barkhof has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EISAI. Dr. Belachew has received personal compensation for serving as an employee of Biogen Inc. Dr. Belachew has received stock or an ownership interest from Biogen Inc.